Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 5;47(1):541.
doi: 10.1007/s10143-024-02783-5.

Interleukin 6 and cancer resistance in glioblastoma multiforme

Donald Detchou  1 , Umaru Barrie  2
Affiliations
Review

Interleukin 6 and cancer resistance in glioblastoma multiforme

Donald Detchou et al. Neurosurg Rev. .

Abstract

Despite unprecedented survival in patients with glioblastoma (GB), the aggressive primary brain cancer remains largely incurable and its mechanisms of treatment resistance have gained particular attention. The cytokine interleukin 6 (IL-6) and its receptor weave through the hallmarks of malignant gliomas and may represent a key vulnerability to GB. Known for activating the STAT3 pathway in autocrine fashion, IL-6 is amplified in GB and has been recognized as a negative biomarker for GB prognosis, rendering it a putative target of novel GB therapies. While it has been recognized as a biologically active component of GB for three decades only with concurrent advances in understanding of complementary immunotherapy has the concept of targeting IL-6 for a human clinical trial gained scientific footing.

Keywords: Glioblastoma; Interleukin 6; STAT3; Tocilizumab.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Coward J, Kulbe H, Chakravarty P et al (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clin cancer Research: Official J Am Association Cancer Res 17(18):6083–6096
    1. Fizazi K, De Bono JS, Flechon A et al (2012) Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 48(1):85–93 - PubMed
    1. Rossi JF, Negrier S, James ND et al (2010) A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 103(8):1154–1162 - PubMed - PMC
    1. Kudo M, Jono H, Shinriki S et al (2009) Antitumor effect of humanized anti–interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. J Neurosurg 111(2):219–225 - PubMed
    1. Jahangiri A, Chin AT, Flanigan PM, Chen R, Bankiewicz K, Aghi MK (2017) Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg 126(1):191–200 - PubMed

LinkOut - more resources